Gain Therapeutics, Inc. (NASDAQ:GANX - Get Free Report) saw unusually large options trading activity on Monday. Investors bought 9,475 call options on the stock. This represents an increase of 5,474% compared to the average daily volume of 170 call options.
Institutional Investors Weigh In On Gain Therapeutics
Institutional investors and hedge funds have recently bought and sold shares of the business. Kovitz Investment Group Partners LLC bought a new stake in Gain Therapeutics in the 1st quarter valued at $91,000. Dauntless Investment Group LLC bought a new stake in Gain Therapeutics in the 1st quarter valued at $240,000. Marshall Wace LLP increased its holdings in Gain Therapeutics by 41.0% in the 2nd quarter. Marshall Wace LLP now owns 276,433 shares of the company's stock valued at $498,000 after buying an additional 80,407 shares during the period. Finally, Geode Capital Management LLC increased its holdings in Gain Therapeutics by 2.9% in the 2nd quarter. Geode Capital Management LLC now owns 290,462 shares of the company's stock valued at $523,000 after buying an additional 8,251 shares during the period. Institutional investors own 11.97% of the company's stock.
Gain Therapeutics Stock Performance
GANX stock traded up $0.29 on Monday, reaching $2.21. 895,427 shares of the company were exchanged, compared to its average volume of 332,327. Gain Therapeutics has a 12 month low of $1.41 and a 12 month high of $3.19. The stock's fifty day moving average price is $1.71 and its 200 day moving average price is $1.79. The firm has a market capitalization of $79.45 million, a PE ratio of -3.53 and a beta of 0.11. The company has a debt-to-equity ratio of 0.09, a current ratio of 1.79 and a quick ratio of 1.79.
Gain Therapeutics (NASDAQ:GANX - Get Free Report) last announced its earnings results on Tuesday, August 12th. The company reported ($0.19) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.17) by ($0.02). On average, research analysts anticipate that Gain Therapeutics will post -1 EPS for the current fiscal year.
Analyst Upgrades and Downgrades
GANX has been the subject of a number of research analyst reports. Weiss Ratings reissued a "sell (e+)" rating on shares of Gain Therapeutics in a research report on Saturday, September 27th. HC Wainwright reissued a "buy" rating and issued a $8.00 price target on shares of Gain Therapeutics in a research report on Thursday, July 3rd. BTIG Research reissued a "buy" rating and issued a $9.00 price target on shares of Gain Therapeutics in a research report on Monday, September 8th. Finally, Roth Capital reduced their price target on shares of Gain Therapeutics from $7.00 to $6.00 and set a "buy" rating for the company in a research report on Wednesday, August 13th. Six analysts have rated the stock with a Buy rating and one has issued a Sell rating to the company's stock. According to data from MarketBeat.com, the stock currently has an average rating of "Moderate Buy" and a consensus target price of $8.00.
Check Out Our Latest Report on Gain Therapeutics
Gain Therapeutics Company Profile
(
Get Free Report)
Gain Therapeutics, Inc, a biotechnology company, develops novel small molecule therapeutics to treat diseases across various therapeutic areas. Its drug discovery platform Magellan discovers novel allosteric binding sites in a disease; identifies proprietary small molecules that bind these sites to modulate protein function; and treats the underlying cause of the disease.
Read More
This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.
Before you consider Gain Therapeutics, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Gain Therapeutics wasn't on the list.
While Gain Therapeutics currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Thinking about investing in Meta, Roblox, or Unity? Enter your email to learn what streetwise investors need to know about the metaverse and public markets before making an investment.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
